Close Menu

NEW YORK (GenomeWeb) – UK-based life science reagents and tools company Abcam announced today that it made a takeover offer for Horizon Discovery on April 19 that valued the company at approximately £270 million ($367.4 million). Horizon's board has rejected the offer.

The offer put a value of 181 pence per share on Horizon's stock, representing a premium of approximately 26 percent to Horizon's closing share price of 144 pence on May 1. The deal would have been satisfied by the issue of new shares in Abcam, the firm said.

Horizon declined to comment on the takeover offer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.